AstraZeneca has begun a phase 3 clinical trial to evaluate its diabetes drug Farxiga (dapagliflozin) as a possible treatment for hospitalized COVID-19 patients.
Source: Drug Industry Daily
AstraZeneca has begun a phase 3 clinical trial to evaluate its diabetes drug Farxiga (dapagliflozin) as a possible treatment for hospitalized COVID-19 patients.
Source: Drug Industry Daily